The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Open accessAbstract
Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms. From retrospective and a few prospective studies it has been suggested that octreotide exhibits antiproliferative properties. The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients. Octreotide treatment was continued in those patients responding to the drug until tumour progression occurred. In 28 of those with tumour progression during 200 micrograms thrice daily octreotide dose was increased to 500 micrograms thrice daily. The study sample consisted of 52 patients with computed tomography confirmed tumour progression and 13 patients with stable disease before octreotide treatment, whereas no preobservation period was available in 38 patients. Nineteen patients (36.5%) with computed tomography confirmed tumour progression experienced stabilisation of tumour growth lasting for at least three months. Median duration of stable disease was 18 months. At month 12, stable disease continued in 12 patients, declined after 24 months to nine patients, and after 36 months to five patients. Tumour regression has not been seen in this or other subgroups. In the subgroup with stable disease before octreotide, stable disease continued in 53.8% of patients over 12 months. Increase of octreotide dose to 500 micrograms thrice daily did not influence progression seen during the lower dose with the exception of one patient in whom tumour progression changed to stable disease. No association of tumour size response and patients' characteristics could be detected. The results suggest that octreotide inhibits tumour growth in patients with metastasised endocrine GEP tumours. The antiproliferative effect is, at least in some patients, longlasting. Currently, octreotide can only be recommended as an antiproliferative drug if patients with clearly progressive disease show stabilisation after treatment for three to six months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032101 · Cited by 659
Öberg, K., Funa, K., & Alm, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307213090301 · Cited by 275
Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260
Gorden, P., Comi, R. J., Maton, P. N., & Go, V. L. W. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-1-35 · Cited by 258
Revised Classification of Neuroendocrine Tumors of the Lung, Pancreas and Gut
Capella, C., Heitz, P. U., Höfler, H., Solcia, E., & Klöppel, G. (1994) · Digestion · doi:10.1159/000201197 · Cited by 186
Treatment of Metastatic Islet Cell Carcinoma with a Somatostatin Analogue (SMS 201-995)
KVOLS, L. K., BUCK, M., MOERTEL, C. G., SCHUTT, A. J., RUBIN, J., O'CONNELL, M. J., & HAHN, R. G. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-162 · Cited by 168
Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors
Maton, P. N., Gardner, J. D., & Jensen, R. T. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536043 · Cited by 135
Carcinoids: The association of histologic growth pattern and survival
Johnson, L. A., Lavin, P. T., Moertel, C. G., Weiland, L. H., Dayal, Y., Doos, W. G., Geller, S. A., Cooper, H. S., Nime, F. A., Massé, S., et al. (1983) · Cancer · doi:10.1002/1097-0142(19830301)51:5<882::aid-cncr2820510522>3.0.co;2-8 · Cited by 117
Ruskon�, A., Ren�, E., Chayvialle, J. A., Bonin, N., Pignal, F., Kremer, M., Bonfils, S., & Rambaud, J. C. (1982) · Digestive Diseases and Sciences · doi:10.1007/bf01295657 · Cited by 106
Use of somatostatin analog in management of carcinoid syndrome
Vinik, A. I., & Moattari, A. R. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536042 · Cited by 104
Somatostatin and Analogues in the Treatment of Cancer
Evers, B. M., Parekh, D., Townsend, C. M., et al. (1991) · Annals of Surgery · doi:10.1097/00000658-199103000-00002 · Cited by 71
Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide
Joensuu, H., Kätkä, K., & Kujari, H. P. (1992) · European Journal of Endocrinology · doi:10.1530/acta.0.1260184 · Cited by 37
Imaging for Pancreatic Endocrine Tumor Localization: Recent Advances
Orbuch, M., Doppman, J. L., Strader, D. B., Fishbeyn, V. A., Benya, R. V., Metz, D. C., & Jensen, R. T. (2015) · Frontiers of gastrointestinal research · doi:10.1159/000423505 · Cited by 36
Somatostatin receptors in the gastrointestinal tract in health and disease.
Reubi, J. C. (1993) · PubMed · Cited by 31
Endocrine tumours of the pancreas
Lo, C., & Fan, S. (2001) · Annals of the College of Surgeons Hong Kong · doi:10.1046/j.1442-2034.2001.00104.x · Cited by 7
Cited by
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Self-citationRamage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Metadata
- Authors
- Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., & Dennler, H. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1996-03
- Volume
- 38
- Issue
- 3
- Pages
- 430-438
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2107436826
- Cited by
- 342
- References
- 18
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.